[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571122":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":75,"collaborators":11,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":11,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":11,"enrollmentInfo":86,"targetDuration":11,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Avistone Biotechnology Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ANS03 monotherapy","EXPERIMENTAL",null,[13],"Drug: ANS03",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","ANS03","ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Avistone Clinical Study Information Center","CONTACT","8610 84148921","information.center@avistonebio.com",[27,40,51,59,67],{"facility":28,"status":29,"city":30,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":11},"Memorial Sloan Kettering Cancer Center","RECRUITING","New York","10022","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-74.00597,40.71427,{"lat":38,"lon":37},{"facility":41,"status":29,"city":42,"state":43,"zip":11,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":50,"contacts":11},"Research Site","Fuzhou","Fujian","China","CN",{"type":35,"coordinates":47},[48,49],119.30611,26.06139,{"lat":49,"lon":48},{"facility":41,"status":29,"city":52,"state":53,"zip":11,"country":44,"countryCode":45,"cosmosGeoPoint":54,"geoPoint":58,"contacts":11},"Guangzhou","Guangdong",{"type":35,"coordinates":55},[56,57],113.25,23.11667,{"lat":57,"lon":56},{"facility":41,"status":29,"city":60,"state":61,"zip":11,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":11},"Shanghai","Shanghai Municipality",{"type":35,"coordinates":63},[64,65],121.45806,31.22222,{"lat":65,"lon":64},{"facility":41,"status":29,"city":68,"state":69,"zip":11,"country":44,"countryCode":45,"cosmosGeoPoint":70,"geoPoint":74,"contacts":11},"Chengdu","Sichuan",{"type":35,"coordinates":71},[72,73],104.06667,30.66667,{"lat":73,"lon":72},{"type":76,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100571122","phase-1-a-study-to-investigate-ans03-in-participants-with-locally-advanced-or-metastatic-solid-tumors-100571122",false,"NCT06716138","A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2\n* Life expectancy ≥ 12 weeks\n* Measurable disease per RECIST v1.1\n* Adequate organ and marrow function as defined in the protocol\n* With documentation of ROS1 or NTRK alteration\n\nExclusion Criteria:\n\n* Active infection including tuberculosis and HBV, HCV or HIV\n* Known active or untreated CNS metastases\n* Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression\n* Participants with serious cardiovascular or cerebrovascular diseases","ALL","18 Years",{"count":87,"type":88},96,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.",[94],"Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration",[96,17,97,98],"ROS1\u002FNTRK","ROS1","NTRK","2026-03-11",{"date":101,"type":102},"2026-03-13","ACTUAL",{"date":104,"type":102},"2025-03-06",{"date":106,"type":88},"2029-03-30",{"name":5,"class":6},5]